State of New Jersey Common Pension Fund D Invests $659,000 in Ocular Therapeutix, Inc. $OCUL

State of New Jersey Common Pension Fund D acquired a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 54,245 shares of the biopharmaceutical company’s stock, valued at approximately $659,000.

A number of other hedge funds also recently made changes to their positions in OCUL. The Manufacturers Life Insurance Company increased its stake in Ocular Therapeutix by 1.8% in the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock valued at $674,000 after acquiring an additional 1,314 shares during the last quarter. Trust Co. of Vermont lifted its stake in Ocular Therapeutix by 24.3% during the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,750 shares during the last quarter. Profund Advisors LLC boosted its holdings in shares of Ocular Therapeutix by 9.9% in the 3rd quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 2,272 shares in the last quarter. Rafferty Asset Management LLC increased its position in shares of Ocular Therapeutix by 21.2% during the 2nd quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 2,343 shares during the last quarter. Finally, Creative Planning increased its position in shares of Ocular Therapeutix by 14.6% during the 3rd quarter. Creative Planning now owns 24,535 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 3,125 shares during the last quarter. 59.21% of the stock is owned by institutional investors.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 124,882 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total transaction of $1,128,933.28. Following the completion of the transaction, the insider owned 3,033,078 shares of the company’s stock, valued at $27,419,025.12. This represents a 3.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard L. Md Lindstrom acquired 60,229 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was acquired at an average price of $7.66 per share, for a total transaction of $461,354.14. Following the completion of the transaction, the director owned 246,933 shares in the company, valued at approximately $1,891,506.78. The trade was a 32.26% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 185,731 shares of company stock worth $1,653,407 over the last 90 days. 2.30% of the stock is owned by insiders.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock opened at $9.28 on Tuesday. The company’s fifty day simple moving average is $9.08 and its two-hundred day simple moving average is $10.48. Ocular Therapeutix, Inc. has a 12-month low of $6.23 and a 12-month high of $16.44. The firm has a market cap of $2.03 billion, a PE ratio of -6.36 and a beta of 0.93. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12.

Analysts Set New Price Targets

OCUL has been the subject of a number of recent research reports. Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Needham & Company LLC reissued a “buy” rating and set a $18.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Tuesday, April 21st. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.